JHVEPhoto Introduction One of the most fascinating things about the stock market is the number of unique companies/stocks we can pick from. Especially in the United States, there seems to be a ticker for every type of business imaginable. However, this also comes with challenges. DexCom, Inc. (DXCM) is a great example of a fast-growing company that has become a disruptor in the healthcare space by offering advanced continuous glucose monitors ("CGM"). This industry is booming and resulted in a total return ...

These stocks have increased their payouts for decades.Dividend growth stocks can make for ideal investment options whether you're a retiree or a long-term investor. The types of businesses that increase their payouts on a regular basis normally have a lot of consistency in their earnings from one year to the next, making them safe investments. That doesn't mean that all dividend growth stocks are safe options, but many of them are.Three of the safer ones you can put in your portfolio today are Abbott Labora ...

Abbott (ABT) closed the latest trading day at $117.11, indicating a +0.58% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily gain of 0.45%. Meanwhile, the Dow lost 0.23%, and the Nasdaq, a tech-heavy index, added 0.84%.The maker of infant formula, medical devices and drugs's shares have seen an increase of 8.01% over the last month, surpassing the Medical sector's gain of 3.16% and the S&P 500's gain of 2.54%.Analysts and investors alike will be keeping a c ...

Abbott Laboratories (ABT) recently made Lingo, its continuous glucose monitoring (CGM) system, available in the United States without a prescription. The system comes with a biosensor and a mobile app designed for consumers’ overall health improvement and wellness.The latest U.S. availability of Lingo helps Abbott expand its market presence in the CGM segment.Following the news, shares of ABT fell 1.1% to $113.10 yesterday. However, as the company is gaining a high level of synergies from its continued deve ...

Abbott Laboratories announced Thursday its over-the-counter continuous glucose monitor Lingo is available in the U.S. starting at $49. Lingo is part of an emerging class of consumer-friendly biosensors that people can use to learn how their bodies respond to food, exercise, sleep and stress. These devices, called continuous glucose monitors, are small sensors that stick through the skin to measure real-time glucose levels. Glucose is a sugar molecule that comes from food, and it's the body's main energy sou ...

Designed for people interested in improving their overall health and wellnessProvides real-time glucose data and personal coaching insights based on the body's reaction to nutrition, exercise and life's daily stressorsAvailable without a prescription; explore different purchase options at www.hellolingo.com  ABBOTT PARK, Ill., Sept. 5, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced U.S. availability of Lingo™, the company's first continuous glucose monitoring system available without a prescription ...

Abbott (ABT) is experiencing strong growth in routine diagnostics owing to increased domestic and international demand. Within Established Pharmaceuticals (“EPD”), the company is driving robust growth in key therapeutic areas, advancing in the biosimilar strategy and establishing financial stability. However, the declining COVID-testing sales and currency fluctuations may restrict Abbott’s growth potential.In the past year, this Zacks Rank #3 (Hold) stock has increased 11.2% compared with the 15.5% rise of ...

The U.S. FDA granted Abbott Breakthrough Device designation to explore deep brain stimulation (DBS) for treatment-resistant depression (TRD) as an option to improve the lives of people with this debilitating conditionApproximately 2.8 million Americans each year are diagnosed with TRD, a form of major depressive disorder that has not responded to two or more treatments1 ABBOTT PARK, Ill., Sept. 4, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) announced today it has initiated a pivotal clinical trial, called the T ...

The most recent trading session ended with Abbott (ABT) standing at $114.66, reflecting a +1.23% shift from the previouse trading day's closing. This change outpaced the S&P 500's 2.12% loss on the day. At the same time, the Dow lost 1.51%, and the tech-heavy Nasdaq lost 3.26%.Heading into today, shares of the maker of infant formula, medical devices and drugs had gained 4.27% over the past month, lagging the Medical sector's gain of 5.45% and the S&P 500's gain of 5.78% in that time.Investors will be eager ...

LAS VEGAS, NEVADA - JANUARY 10: An Abbott logo is displayed at the company's booth during CES 2024 ... [+] at the Las Vegas Convention Center on January 10, 2024 in Las Vegas, Nevada. CES, the world's largest annual consumer technology trade show, runs through January 12 and features about 4,000 exhibitors showing off their latest products and services to more than 130,000 attendees. (Photo by Ethan Miller/Getty Images)Getty ImagesGiven its better prospects, we believe Abbott stock (NYSE: ABT) is a better p ...